Inventiva Stock (NASDAQ:IVA), Quotes and News Summary

Q: How do I buy Inventiva (IVA) stock?

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage. View our list of the best stock brokerages.

Q: Who are Inventiva's (IVA) competitors?

Other companies in Inventiva’s space includes: Zura Bio (NASDAQ:ZURA) , Syros Pharmaceuticals (NASDAQ:SYRS) , bluebird bio (NASDAQ:BLUE) , Atossa Therapeutics (NASDAQ:ATOS) and GlycoMimetics (NASDAQ:GLYC) .

Q: What is the target price for Inventiva (IVA) stock?

The latest price target for Inventiva (NASDAQ: IVA) was reported by Canaccord Genuity on Monday, April 8, 2024. The analyst firm set a price target for 20.00 expecting IVA to rise to within 12 months (a possible 500.60% upside). 13 analyst firms have reported ratings in the last year.

Q: Current Stock Price for Inventiva (IVA)?

The stock price for Inventiva (NASDAQ: IVA) is $3.33 last updated April 18, 2024 at 7:50 AM EDT.

Q: Does Inventiva (IVA) pay a dividend?

There are no upcoming dividends for Inventiva.

Q: When is Inventiva (NASDAQ:IVA) reporting earnings?

Inventiva’s FY earnings are confirmed for Tuesday, April 30, 2024.

Q: Is Inventiva (IVA) going to split?

There is no upcoming split for Inventiva.

Q: What sector and industry does Inventiva (IVA) operate in?

Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Inventiva Stock (NASDAQ: IVA) stock price, news, charts, stock research, profile.

Open	$3.220
Close	$3.450
Volume / Avg.	11.854K / 40.027K
Day Range	3.220 - 3.470
52 Wk Range	2.220 - 5.050
Market Cap	$173.546M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	39
Short Interest	0.16%
Days to Cover	1

Recent News

Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.

Avi Kapoor

Why Is Liver Disease-Focused Inventiva Stock Trading Lower Today?

Inventiva announces a voluntary pause in NATiV3 Phase 3 trial of lanifibranor for NASH due to a treatment-related SUSAR. Screening and randomization halted temporarily.

Vandana Singh

Why The Trade Desk Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Shares of The Trade Desk, Inc. (NASDAQ: TTD) shares rose sharply in today’s pre-market trading after the company reported mixed fourth-quarter financial results<

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trend

Oct 23

Dec 23

Feb

Mar

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

About Inventiva

Sector

Health Care

Industry

Biotechnology

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Inventiva (IVA) stock?

You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.

View our list of the best stock brokerages.

Who are Inventiva's (IVA) competitors?

Other companies in Inventiva’s space includes: Zura Bio (NASDAQ:ZURA), Syros Pharmaceuticals (NASDAQ:SYRS), bluebird bio (NASDAQ:BLUE), Atossa Therapeutics (NASDAQ:ATOS) and GlycoMimetics (NASDAQ:GLYC).

What is the target price for Inventiva (IVA) stock?